BMY
FDA gave BMY a shiny new toy
Bristol Myers Squibb just picked up accelerated FDA approval for Zenbexus (iberdomide) in multiple myeloma, and that’s a legit win for a company that’s been trying to keep its growth story from turning into a sequel nobody asked for. The drug is now cleared for use with daratumumab, hyaluronidase-fihj, and dexamethasone in adults who’ve already had at least one prior therapy line.
Why investors should care
This isn’t just a science-fair ribbon. Zenbexus is the first FDA-approved CELMoD, which sounds like something a Marvel villain would invent, but in plain English it means Bristol Myers now has a new commercial asset in a big oncology market. The approval was backed by Phase 3 EXCALIBER-RRMM data showing a higher MRD-negative complete response rate — 41% versus 21% for the comparator combo — and that kind of clinical edge is what can turn a drug from “nice press release” into “real money.”
The catch: approval is not the finish line
Accelerated approval means Bristol Myers still needs confirmatory trial data to lock in the full story. So yes, this is a step forward, but the company still has to do the less glamorous part: convincing doctors, payers, and patients that Zenbexus is worth the wallet hit.
William Blair pegged the drug at roughly $29,500 per 28-day cycle, and analysts are already modeling more than $1 billion in annual U.S. sales by early 2031. That’s the kind of number that makes a pharma CFO sit up straighter.
Big picture
Bristol Myers needs fresh growth engines, and Zenbexus just became one of them. The market may still be debating valuation and pipeline risk, but this approval gives BMY a concrete reason to stay in the oncology conversation.